SUMMARY
# Protein Aggregation Kinetic Validation Results
## Background and Rationale
This validation study aims to experimentally verify computational predictions of protein aggregation kinetics using Thioflavin-T (ThT) fluorescence assays, addressing a critical gap in neurodegeneration research where protein misfolding and aggregation drive pathology. Protein aggregation is a hallmark of neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease, making accurate prediction
METHODOLOGY NOTES
Phase 1: Protein Preparation and Quality Control (Days 1-3) - Express and purify target proteins using established protocols, confirm identity by mass spectrometry, assess purity by SDS-PAGE (>95%), and determine concentration by UV-Vis spectroscopy. Store proteins at -80°C in aggregation-compatible buffers. Phase 2: ThT Assay Optimization (Days 4-5) - Prepare fresh 1mM ThT stock solution, optimize ThT concentration (10-50μM range), validate buffer conditions matching computational model parameters (pH 7.4, ionic strength 150mM), and establish baseline fluorescence measurements. Phase 3: Kinetic Aggregation Assays (Days 6-14) - Load 96-well black plates with 200μL reactions containing protein (1-10μM concentrations), ThT (25μM final), and appropriate buffers. Include negative controls (buffer only, ThT only) and positive controls (pre-formed fibrils). Incubate at 37°C with continuous orbital shaking (300rpm). Monitor ThT fluorescence (Ex: 440nm, Em: 480nm) every 10 minutes for 7 days u